XML 1077 R108.htm IDEA: XBRL DOCUMENT v2.4.0.6
COMMITMENTS AND CONTINGENCIES (Details) (Daiichi Sankyo, USD $)
In Millions, unless otherwise specified
 1 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended 12 Months Ended
Apr. 30, 2011
Sep. 30, 2012
Dec. 31, 2011
Jul. 31, 2011
Minimum
country
Sep. 30, 2012
Minimum
Dec. 31, 2011
Minimum
Sep. 30, 2012
Maximum
Dec. 31, 2011
Maximum
Licensing Agreements                
Up-front fee and certain past reimbursements $ 1.6              
Future milestone payments payable   $ 10.0 $ 10.0          
Period for which royalties will be paid following the first commercial sale of licensed products in the country   10 years 10 years          
Notice period for termination of license by the entity for technical, scientific, efficacy, safety, or commercial reasons   6 months 6 months          
Notice period for termination of license after launch of a sapacitabine-based product by the entity, or by either party for material default   12 months 12 months          
Number of countries for which regulatory approval is required by September 2011 to sell sapacitabine as per termination right waived after amendment to the agreement       1        
Percentage of increase in royalty due on future net sales of sapacitabine after amendment         1.25% 1.25% 1.50% 1.50%